Table 2.
Characteristics of the FL efficacy populations.
| Parameter | Result | |
|---|---|---|
| Primary efficacy population (N = 81) | All leukapheresed (N = 123)a,b | |
| Age, years | ||
| Median (range) | 62 (34-79) | 60 (34-79) |
| ≥ 65, n | 29 (36%) | 39 (32%) |
| Diagnosis, n | ||
| FL grade 1-2 | 59 (73%) | 93 (76%) |
| FL grade 3a | 22 (27%) | 30 (24%) |
| Stage III-IV disease, n | 71 (88%) | 105 (85%) |
| Prior lines of systemic therapy, n | ||
| Median (range) | 3 (2-9) | 3 (1-10) |
| 2 | 26 (32%) | 43 (35%) |
| 3 | 18 (22%) | 31 (25%) |
| 4 | 19 (23%) | 25 (20%) |
| 5 or more | 18 (22%) | 20 (16%) |
| Outcome of last therapy | ||
| Type of response | ||
| At least PR | 36 (44%) | 58 (47%) |
| No response | 33 (41%) | 46 (38%) |
| Not evaluable or unknown | 12 (15%) | 18 (15%) |
| Progression within 6 months | 58 (72%) | 83 (67%) |
| POD 24 | 45 (56%) | 67 (54%) |
| Prior regimens | ||
| Lenalidomide + rituximab | 19 (23%) | 26 (21%) |
| PI3K inhibitor | 25 (31%) | 33 (27%) |
Excludes 4 patients diagnosed with FL but found to have aggressive lymphoma after enrollment.
Includes 3 patients who did not receive axicabtagene ciloleucel.
Abbreviations: FL, follicular lymphoma; PI3K, phosphoinositide 3-kinase; POD24, progression of disease within 24 months of first chemoimmunotherapy.